|
|
Preventing prostate Cancer and BPH: Prostate-health Expert Available (National Men's Health Week...
newswise.com May 9, 2008
The risk of the two major prostate diseases, cancer and benign prostatic hyperplasia (BPH), can be reduced by changes in lifestyle, such as avoiding smoking, maintaining a normal weight and eating a healthy diet. Alan Kristal, Dr.P.H., associate head of the Cancer Prevention Program at Fred...
Newstin has read and analyzed this article for you...
What is this article about?
You might be also interested in the following articles found by Newstin:
AEterna Zentaris: First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in...
bionity.com 18 hrs ago 8 related
16 May 2008 - AEterna Zentaris Inc. reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH). Cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist, is the Company's flagship...
Millions suffer from treatable prostate condition
wsbt.com 22 hrs ago
— Millions of men suffer from a prostate condition that is easily treated. Wayne Saker is a busy financial investor, so getting a good night's sleep is important. But his routine was disrupted when he experienced symptoms of an enlarged prostate. “Once you experience it it's a very serious...
Protox doses first patient in Phase 2 BPH clinical trial
newswire.ca yesterday 1 related
VANCOUVER, May 15 /CNW/ - Protox Therapeutics Inc. (TSX:PRX), a leader in the development of receptor targeted fusion proteins, today announced the enrolment and successful dosing of the first patient in a Phase 2 clinical trial evaluating PRX302 to treat benign prostatic hyperplasia (BPH), or...
Trimedyne Reports Financial Results for the Quarter Ended March 31, 2008
tmcnet.com yesterday
equivalents, receivables of $721,000, other current assets of $250,000 and inventories of $3,064,000, versus accounts payable of $345,000, accrued expenses of $442,000 and equipment lease debt of $368,000. Marvin P. Loeb, CEO of Trimedyne, said, "We incurred a significant increase in research and...